Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,742 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,104 of 1,171 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,884 total, page 16 of 38
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
NCT04242238
Ultrasound-Guided Serratus Anterior Plane Block for Additional Pain Relief After Lung Surgery
NCT04238455
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
NCT04635735
Studying a New Piece of Equipment That Can Help Plan Radiation Therapy of the Spine
NCT04227717
Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment
NCT04210128
Chemoembolization for Lung Tumors
NCT04200417
Communication Training for Caregivers In Advanced Care Planning
NCT04171895
Bleeding in Critically Ill Children With Underlying Oncologic Diagnoses
NCT04170231
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
NCT04161781
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
NCT04173104
Supportive Care Delivered by Telemedicine to Cancer Patients at Home
NCT04136340
A Study of the Experience of Music Therapy in Cancer Patients With Delirium
NCT04104217
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
NCT04095221
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
NCT04068831
Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
NCT04054986
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
NCT04051502
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
NCT04040231
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
NCT04017962
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
NCT04019327
Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction
NCT04016376
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
NCT03939182
Study of Nutritional Supplement Shakes in People About to Receive Their Debulking Surgery for Ovarian Cancer
NCT03956095
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
NCT03947346
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
NCT03909152
Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis
NCT03929822
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
NCT03922880
A Study of a Device Used to Take Pictures of Skin Blood Flow
NCT03912376
Automated Geriatric Co-Management Program in Older Patients With Solid Mass or Nodule Suspicious for Cancer
NCT03885908
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
NCT03879798
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
NCT03877055
A Study of Olaparib and Durvalumab in Prostate Cancer
NCT03810105
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
NCT03866460
Comparing Distress Screening + Consultation With Enhanced Usual Care for Caregivers of Cancer Patients
NCT03856086
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
NCT03843775
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
NCT03843593
Managing Anxiety From Cancer (MAC): Testing an Intervention for Anxiety in Older Adults With Cancer and Their Caregivers
NCT03168971
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
NCT03703167
Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
NCT03817814
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
NCT03810807
Continued Access to RXDX-105
NCT03784378
Trial of IRE in Cholangiocarcinoma
NCT03769753
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
NCT03767257
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
NCT03755102
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
NCT03681483
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT03693807
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
NCT03704688
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NCT03667482
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
NCT03665155
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT03581942
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
NCT03643510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Memorial Sloan Kettering Cancer Center: open-pipeline peers nationwide
Peers matched on 1,884 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Memorial Sloan Kettering Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,884 trials (± recruiting share)
- Pfizer · 1,845 trials · 6% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- ImmunityBio · 17% recruiting · 46 trials
- Old Dominion University · 17% recruiting · 23 trials
- Texas Tech University · 17% recruiting · 69 trials
- TransMedics · 17% recruiting · 23 trials
Related
What to do with this Memorial Sloan Kettering Cancer Center page
1,884 registered trials is a research-attention snapshot, not an endorsement of Memorial Sloan Kettering Cancer Center or any single study.
- 327 of Memorial Sloan Kettering Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Memorial Sloan Kettering Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Memorial Sloan Kettering Cancer Center pipeline card: 1,884 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.